مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

video

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

sound

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Version

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

View:

272
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Download:

166
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Cites:

Information Journal Paper

Title

A PLACEBO-CONTROLLED STUDY OF RALOXIFENE ADDED TO RISPERIDONE IN MEN WITH CHRONIC SCHIZOPHRENIA

Pages

  337-345

Abstract

 Selective ESTROGEN receptor modulators (SERMs) such as RALOXIFENE have already shown beneficial effects on negative, positive and general psychopathology symptoms in postmenopausal women with SCHIZOPHRENIA. The purpose of the present investigation was to assess the efficacy of RALOXIFENE as an adjuvant agent in the treatment of MEN with chronic SCHIZOPHRENIA in an 8-week double-blind and placebocontrolled trial. In a randomized, double-blind and placebo-controlled study, forty-six male patients diagnosed with SCHIZOPHRENIA (DSM-IV-TR), were randomized to either RALOXIFENE (120 mg/day) or placebo in addition to risperidone (6 mg/day) for eight weeks. The assessment was performed using the positive and negative symptom scale (PANSS) at baseline, and at weeks 2, 4, 6 and 8. Extrapyramidal symptom rating scale (ESRS) at baseline, weeks 1, 2, 4, 6, 8 and Hamilton depression rating scale (HDRS) at baseline and week 8 were also used to assess extrapyramidal symptoms and depression simultaneously. Forty-two patients completed the trial. The RALOXIFENE group showed significantly greater improvement on the negative subscale (P<0.001), the general psychopathology subscale (P=0.002) and total PANSS score (P<0.001) in comparison to the placebo group at the endpoint. There was no significant difference in the reduction of positive symptoms score between the two group (P=0.525). Extrapyramidal symptom rating scale and Hamilton depression rating scale and frequency of other adverse effects were comparable between two groups. This study indicates RALOXIFENE as a potential adjunctive treatment strategy for chronic SCHIZOPHRENIA in MEN.

Cites

  • No record.

    • References

  • No record.

    • Cite

    APA: Copy

    KHODAIE ARDAKANI, MOHAMMAD REZA, KHOSRAVI, MOHSEN, ZARINFARD, RAZIEH, NEJATI, SOMAYEH, MOHSENIAN, ALI, TABRIZI, MINA, & AKHONDZADEH, SHAHIN. (2015). A PLACEBO-CONTROLLED STUDY OF RALOXIFENE ADDED TO RISPERIDONE IN MEN WITH CHRONIC SCHIZOPHRENIA. ACTA MEDICA IRANICA, 53(6), 337-345. SID. https://sid.ir/paper/278689/en

    Vancouver: Copy

    KHODAIE ARDAKANI MOHAMMAD REZA, KHOSRAVI MOHSEN, ZARINFARD RAZIEH, NEJATI SOMAYEH, MOHSENIAN ALI, TABRIZI MINA, AKHONDZADEH SHAHIN. A PLACEBO-CONTROLLED STUDY OF RALOXIFENE ADDED TO RISPERIDONE IN MEN WITH CHRONIC SCHIZOPHRENIA. ACTA MEDICA IRANICA[Internet]. 2015;53(6):337-345. Available from: https://sid.ir/paper/278689/en

    IEEE: Copy

    MOHAMMAD REZA KHODAIE ARDAKANI, MOHSEN KHOSRAVI, RAZIEH ZARINFARD, SOMAYEH NEJATI, ALI MOHSENIAN, MINA TABRIZI, and SHAHIN AKHONDZADEH, “A PLACEBO-CONTROLLED STUDY OF RALOXIFENE ADDED TO RISPERIDONE IN MEN WITH CHRONIC SCHIZOPHRENIA,” ACTA MEDICA IRANICA, vol. 53, no. 6, pp. 337–345, 2015, [Online]. Available: https://sid.ir/paper/278689/en

    Related Journal Papers

  • No record.

    • Related Seminar Papers

  • No record.

    • Related Plans

  • No record.

    • Recommended Workshops






    Move to top
    telegram sharing button
    whatsapp sharing button
    linkedin sharing button
    twitter sharing button
    email sharing button
    email sharing button
    email sharing button
    sharethis sharing button